| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/23/2008 | EP1913947A1 Combination therapy for the treatment of cancer |
| 04/23/2008 | EP1913946A1 Therapeutic agent and treatment method for ameliorating uremia |
| 04/23/2008 | EP1913945A2 Composition based on a thiazolidinedione and metformin and its use |
| 04/23/2008 | EP1913944A1 Pharmaceutical combinations and their use in treating gastrointestinal disorders |
| 04/23/2008 | EP1913943A1 Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria |
| 04/23/2008 | EP1913942A2 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| 04/23/2008 | EP1913941A1 Polymorphic forms and solvates of Cinacalcet hydrochloride |
| 04/23/2008 | EP1913940A1 Rhein conjugates, preparation method thereof and their uses in producing medicines for treating diabetic nephrosis, intestinal adhesion and osteoarthritis |
| 04/23/2008 | EP1913939A1 Formulations for use in inhaler devices |
| 04/23/2008 | EP1913938A1 Transdermal buprenorphine dosage regimen for analgesia |
| 04/23/2008 | EP1913937A1 Guaifenesin sustained release formulation and tablets |
| 04/23/2008 | EP1913936A1 Sublingual solid pharmaceutical formulations containing meloxicam |
| 04/23/2008 | EP1913935A1 Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
| 04/23/2008 | EP1913821A1 Polyphenol-rich extract from plant material |
| 04/23/2008 | EP1913400A2 Il-32 modulators |
| 04/23/2008 | EP1913398A2 Treatment of proliferative disorders |
| 04/23/2008 | EP1913397A1 Graded expression of snail as marker of cancer development and dna damage-based diseases |
| 04/23/2008 | EP1913137A1 Serine beta-lactamase-like / d-aia carboxypeptidase-like protein |
| 04/23/2008 | EP1913015A1 Macrocyclic inhibitors of hepatitis c virus |
| 04/23/2008 | EP1913014A1 Macrocyclic inhibitors of hepatitis c virus |
| 04/23/2008 | EP1913012A2 Oligomers of cholesterol, cholesterol sulfate and cholesterol esters, and medicaments containing the same |
| 04/23/2008 | EP1913004A1 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents |
| 04/23/2008 | EP1913003A1 NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES |
| 04/23/2008 | EP1913001A2 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
| 04/23/2008 | EP1912999A1 Macrocyclic inhibitors of hepatitis c virus |
| 04/23/2008 | EP1912998A1 Pyrazole derivatives having tyrosinkinase activity |
| 04/23/2008 | EP1912997A1 Macrocylic inhibitors of hepatitis c virus |
| 04/23/2008 | EP1912996A1 Macrocyclic inhibitors of hepatitis c virus |
| 04/23/2008 | EP1912994A1 Adenine derivatives |
| 04/23/2008 | EP1912993A1 Xanthine derivatives as selective hm74a agonists |
| 04/23/2008 | EP1912992A1 Xanthine derivatives as selective hm74a agonists |
| 04/23/2008 | EP1912991A1 Xanthine derivatives as selective hm74a agonists |
| 04/23/2008 | EP1912990A1 Hydrochlorides and hydrates of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their preparation and their use as medicaments |
| 04/23/2008 | EP1912989A2 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| 04/23/2008 | EP1912988A1 7-substituted aza-indazoles, compositions containing same, production method and use thereof |
| 04/23/2008 | EP1912987A1 Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| 04/23/2008 | EP1912986A1 Imidiazo -and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| 04/23/2008 | EP1912985A1 Imidazopyridine derivatives as cannabinoid receptor ligands |
| 04/23/2008 | EP1912983A2 Modulators of cystic fibrosis transmembrane conductance regulator |
| 04/23/2008 | EP1912982A2 Novel heterocyclic nf- b inhibitors |
| 04/23/2008 | EP1912980A2 Oxazolidinones bearing antimicrobial activity composition and methods of preparation |
| 04/23/2008 | EP1912979A2 Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
| 04/23/2008 | EP1912978A2 Ppar / agonists and processes of preparing |
| 04/23/2008 | EP1912977A1 Ep4 receptor agonist, compositions and methods thereof |
| 04/23/2008 | EP1912976A1 Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists |
| 04/23/2008 | EP1912974A1 Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
| 04/23/2008 | EP1912973A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 04/23/2008 | EP1912972A1 Substituted imidazole compounds as ksp inhibitors |
| 04/23/2008 | EP1912971A2 Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| 04/23/2008 | EP1912969A1 Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents |
| 04/23/2008 | EP1912968A1 Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| 04/23/2008 | EP1912967A1 Quinoline derivatives as neurokinin receptor antagonists |
| 04/23/2008 | EP1912966A2 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system |
| 04/23/2008 | EP1912964A2 Dihydroxyanthraquinones and their use |
| 04/23/2008 | EP1912963A2 Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease |
| 04/23/2008 | EP1912962A2 Crystalline non-solvated methanesulfonic acid salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene |
| 04/23/2008 | EP1912960A1 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound and use thereof as a hypolipidaemic |
| 04/23/2008 | EP1912959A2 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors |
| 04/23/2008 | EP1912957A1 Ep4 receptor agonist, compositions and methods thereof |
| 04/23/2008 | EP1912954A2 Novel cysteine protease inhibitors and their therapeutic applications |
| 04/23/2008 | EP1912952A1 Process for preparing amorphous rosuvastatin calcium free of impurities |
| 04/23/2008 | EP1912949A1 Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
| 04/23/2008 | EP1912948A1 Antibacterial quinoline derivatives |
| 04/23/2008 | EP1912947A1 Isotopically substituted pantoprazole |
| 04/23/2008 | EP1912946A1 Pyridine derivatives as dipeptedyl peptidase inhibitors |
| 04/23/2008 | EP1912945A1 N-(pyridin-4-yl)-2-phenylbutanamides as androgen receptor modulators |
| 04/23/2008 | EP1912944A1 New salt iii |
| 04/23/2008 | EP1912943A1 New salt i |
| 04/23/2008 | EP1912942A1 Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases. |
| 04/23/2008 | EP1912941A1 Novel piperidine derivatives |
| 04/23/2008 | EP1912940A1 Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| 04/23/2008 | EP1912939A1 Metabotropic glutamate-receptor-potentiating isoindolones |
| 04/23/2008 | EP1912938A2 Salts of vildagliptin |
| 04/23/2008 | EP1912937A1 Novel substituted azetidinones |
| 04/23/2008 | EP1912932A2 Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
| 04/23/2008 | EP1912921A2 Tetraazaporphyrin-based compounds and their uses |
| 04/23/2008 | EP1912708A1 Emulsified skin external preparation and method for stabilizing the skin external preparation |
| 04/23/2008 | EP1912707A2 Ophthalmic compositions containing mucoadhesive polysaccharides able to promote corneal re-epithelization |
| 04/23/2008 | EP1912706A2 Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors |
| 04/23/2008 | EP1912679A2 Amine-containing lipids and uses thereof |
| 04/23/2008 | EP1912658A1 Therapeutic protocols using hyaluronan |
| 04/23/2008 | EP1912657A2 Metered-dose and safety and compliance packaging for systemic anticancer therapy |
| 04/23/2008 | EP1912656A2 Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
| 04/23/2008 | EP1912655A2 Aminoethane sulfonamide orexin receptor antagonists |
| 04/23/2008 | EP1912654A2 Methods for selectively treating cox-2 mediated disorders by administering gamma-tocopherol |
| 04/23/2008 | EP1912653A2 Heterocyclic benzodiazepine cgrp receptor antagonists |
| 04/23/2008 | EP1912652A1 TREATMENT OF TUMOURS WITH IKK-ß INHIBITORS |
| 04/23/2008 | EP1912651A2 Amorphous aprepitant coprecipitates |
| 04/23/2008 | EP1912650A1 Use of flibanserin in the treatment of obesity |
| 04/23/2008 | EP1912649A2 Quinoline derivatives as antibacterial agents |
| 04/23/2008 | EP1912648A2 Quinoline derivatives as antibacterial agents |
| 04/23/2008 | EP1912647A2 Quinoline derivatives as antibacterical agents |
| 04/23/2008 | EP1912646A2 Combinations containing ikk-beta inhibitors |
| 04/23/2008 | EP1912645A2 Therapeutic agent for diabetes |
| 04/23/2008 | EP1912644A2 N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and use thereof |
| 04/23/2008 | EP1912643A2 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| 04/23/2008 | EP1912642A2 Synthesis and crystalline forms of npy5 antagonist |
| 04/23/2008 | EP1912641A2 Methods and compositions containing natural folates for protecting against radiation damage |
| 04/23/2008 | EP1912640A1 Use of hdac inhibitors for the treatment of myeloma |
| 04/23/2008 | EP1912639A2 Thiazolopyrimidine kinase inhibitors |